Inventor
BROOIJMANS NATASJA
US15 patents
⚠️ This page may combine multiple inventors who share the name “BROOIJMANS NATASJA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BLUEPRINT MEDICINES CORP
13 patentsUS9340514B2May 17, 2016
Inhibitors of the fibroblast growth factor receptor
BLUEPRINT MEDICINES CORP43 citations97
US10202365B2Feb 12, 2019
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
BLUEPRINT MEDICINES CORP20 citations94
US10233186B2Mar 19, 2019
Inhibitors of activin receptor-like kinase
BLUEPRINT MEDICINES CORP16 citations93
US10017512B2Jul 10, 2018
Compounds and compositions useful for treating disorders related to NTRK
BLUEPRINT MEDICINES CORP29 citations93
US10774070B2Sep 15, 2020
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
BLUEPRINT MEDICINES CORP6 citations84
US11046697B2Jun 29, 2021
Compounds and compositions useful for treating disorders related to NTRK
BLUEPRINT MEDICINES CORP5 citations72
US11970498B2Apr 30, 2024
CDK2 inhibitors
BLUEPRINT MEDICINES CORP1 citations71
US11718602B2Aug 8, 2023
EGFR inhibitors
BLUEPRINT MEDICINES CORP2 citations70
US11634422B2Apr 25, 2023
Inhibitors of activin receptor-like kinase
BLUEPRINT MEDICINES CORP1 citations70
US12545684B2Feb 10, 2026
CDK2 inhibitors
BLUEPRINT MEDICINES CORP0 citations61
US11932648B2Mar 19, 2024
CDK2 inhibitors
BLUEPRINT MEDICINES CORP1 citations61
US12595265B2Apr 7, 2026
Inhibitors of activin receptor-like kinase
BLUEPRINT MEDICINES CORP0 citations59
US12172983B2Dec 24, 2024
EGFR inhibitors
BLUEPRINT MEDICINES CORP0 citations59